{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T23:47:42Z","timestamp":1771631262390,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ministry of Health Malaysia Research Grant","award":["NIH\/800-3\/2\/2 Jilid 13 (182)"],"award-info":[{"award-number":["NIH\/800-3\/2\/2 Jilid 13 (182)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-024-09679-1","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T06:03:12Z","timestamp":1722837792000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nirmatrelvir\/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia"],"prefix":"10.1186","volume":"24","author":[{"given":"Ee Vien","family":"Low","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohan Dass","family":"Pathmanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi Yang","family":"Ten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh Kumar","family":"Chidambaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wee Ric","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei Jia","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi Wei","family":"Teh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maheshwara Rao","family":"Appannan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mastura","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azah Abdul","family":"Samad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalaiarasu M.","family":"Peariasamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"key":"9679_CR1","unstructured":"Ministry of Health Malaysia. COVID-19: What is latest situation in Malaysia? 2024 https:\/\/data.moh.gov.my\/dashboard\/covid-19. Accessed 15 Dec 2023."},{"issue":"1","key":"9679_CR2","doi-asserted-by":"publisher","first-page":"2027160","DOI":"10.1080\/21645515.2022.2027160","volume":"18","author":"I Mohammed","year":"2022","unstructured":"Mohammed I, Nauman A, Paul P, Ganesan S, Chen KH, Jalil SMS, et al. The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. Hum Vaccin Immunother. 2022;18(1):2027160.","journal-title":"Hum Vaccin Immunother"},{"key":"9679_CR3","unstructured":"Centers for Disease Control and Prevention. Benefits of Getting https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/vaccine-benefits.html. Accessed 15 Dec 2023."},{"key":"9679_CR4","unstructured":"Anand R. PM Muhyiddin receives first Covid-19 vaccine as Malaysia kicks off mass innoculation campaign. Straits Time. 2021."},{"key":"9679_CR5","unstructured":"Ministry of Health Malaysia. COVIDNOW: Vaccination Progress 2023. https:\/\/covidnow.moh.gov.my\/vaccinations\/?refresh=1720781109523. Accessed 1 January 2024."},{"key":"9679_CR6","first-page":"100055","volume":"4","author":"BLH Sim","year":"2020","unstructured":"Sim BLH, Chidambaram SK, Wong XC, Pathmanathan MD, Peariasamy KM, Hor CP, et al. Clinical characteristics and risk factors for severe COVID-19 infections in Malaysia: a nationwide observational study. Lancet Reg Health West Pac. 2020;4:100055.","journal-title":"Lancet Reg Health West Pac"},{"key":"9679_CR7","unstructured":"Centers for Disease Control and Prevention. Underlying Medical Conditions 2023. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-care\/underlyingconditions.html. Accessed 15 Dec 2023."},{"issue":"9","key":"9679_CR8","doi-asserted-by":"publisher","first-page":"e1247","DOI":"10.1016\/S2214-109X(22)00286-8","volume":"10","author":"M Dryden","year":"2022","unstructured":"Dryden M, Mudara C, Vika C, Blumberg L, Mayet N, Cohen C, et al. Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study. Lancet Glob Health. 2022;10(9):e1247\u201356.","journal-title":"Lancet Glob Health"},{"key":"9679_CR9","unstructured":"Centers for Disease Control and Prevention, Long COVID. 2023. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/long-term-effects\/index.html. Accessed 15 Dec 2023."},{"key":"9679_CR10","doi-asserted-by":"publisher","first-page":"101762","DOI":"10.1016\/j.eclinm.2022.101762","volume":"55","author":"LL O\u2019Mahoney","year":"2023","unstructured":"O\u2019Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, et al. The prevalence and long-term health effects of long covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine. 2023;55:101762.","journal-title":"EClinicalMedicine"},{"key":"9679_CR11","unstructured":"National Istitue for Health and Care Excellence (NICE). Royal College of General Practitioner (RCGP); Scottish intercollegiate Guidelines Network (SIGN); COVID-19 rapid guidelines: managing the long term effects of COVID-19. 2022. Accessed 15 Dec 2023."},{"key":"9679_CR12","unstructured":"Government of Canada. Post COVID-19 condition (long COVID) 2023 [updated March 9. 2023. https:\/\/www.canada.ca\/en\/public-health\/services\/diseases\/2019-novel-coronavirus-infection\/symptoms\/post-covid-19-condition.html. Accessed 15 Dec 2023."},{"key":"9679_CR13","unstructured":"Department of Health and Aged Care, Long COVID. 2023 https:\/\/www.health.gov.au\/topics\/covid-19\/long-covid. Accessed 15 Dec 2023."},{"issue":"7","key":"9679_CR14","doi-asserted-by":"publisher","first-page":"ofad233","DOI":"10.1093\/ofid\/ofad233","volume":"10","author":"M Woodrow","year":"2023","unstructured":"Woodrow M, Carey C, Ziauddeen N, Thomas R, Akrami A, Lutje V, et al. Systematic review of the prevalence of long COVID. Open Forum Infect Dis. 2023;10(7):ofad233.","journal-title":"Open Forum Infect Dis"},{"key":"9679_CR15","unstructured":"FDA. FDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults. 2023 https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-oral-antiviral-treatment-covid-19-adults. Accessed 15 Nov 2023."},{"key":"9679_CR16","unstructured":"Aggarwal NR, Molina KC, Beaty LE, Bennett TD, Carlson NE, Mayer DA et al. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. The Lancet Infectious Diseases."},{"issue":"9","key":"9679_CR17","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa2204919","volume":"387","author":"R Arbel","year":"2022","unstructured":"Arbel R, Wolff Sagy Y, Hoshen M, Battat E, Lavie G, Sergienko R, et al. Nirmatrelvir use and severe Covid-19 outcomes during the Omicron Surge. N Engl J Med. 2022;387(9):790\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"9679_CR18","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1093\/cid\/ciac443","volume":"76","author":"R Najjar-Debbiny","year":"2022","unstructured":"Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, et al. Effectiveness of Paxlovid in reducing severe coronavirus Disease 2019 and mortality in high-risk patients. Clin Infect Dis. 2022;76(3):e342\u20139.","journal-title":"Clin Infect Dis"},{"key":"9679_CR19","doi-asserted-by":"crossref","unstructured":"Wai AK-C, Chan CY, Cheung AW-L, Wang K, Chan SC-L, Lee TT-L et al. Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19. Lancet Reg Health \u2013 Western Pac. 2023;30.","DOI":"10.1016\/j.lanwpc.2022.100602"},{"key":"9679_CR20","doi-asserted-by":"crossref","unstructured":"Marzi M, Vakil MK, Bahmanyar M, Zarenezhad E, Paxlovid. Mechanism of action, synthesis, and in Silico Study. Biomed Res Int. 2022;2022:7341493.","DOI":"10.1155\/2022\/7341493"},{"issue":"1","key":"9679_CR21","doi-asserted-by":"publisher","first-page":"19688","DOI":"10.1038\/s41598-023-46912-4","volume":"13","author":"S Congdon","year":"2023","unstructured":"Congdon S, Narrowe Z, Yone N, Gunn J, Deng Y, Nori P, et al. Nirmatrelvir\/ritonavir and risk of long COVID symptoms: a retrospective cohort study. Sci Rep. 2023;13(1):19688.","journal-title":"Sci Rep"},{"key":"9679_CR22","doi-asserted-by":"crossref","unstructured":"Xie Y, Choi T, Al-Aly Z. Association of Treatment with Nirmatrelvir and the risk of Post\u2013COVID-19 Condition. JAMA Internal Medicine; 2023.","DOI":"10.1001\/jamainternmed.2023.0743"},{"key":"9679_CR23","unstructured":"National Pharmaceutical Regulatory Agency. SENARAI PRODUK \u2013 PRODUK YANG TELAH DILULUSKAN OLEH PIHAK BERKUASA KAWALAN DADAH (PBKD.) DALAM MESYUARAT PBKD KALI KE \u2013 370. 2022."},{"key":"9679_CR24","doi-asserted-by":"crossref","unstructured":"Lewnard JA, McLaughlin JM, Malden D, Hong V, Puzniak L, Ackerson BK, et al. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system. The Lancet Infectious Diseases; 2023.","DOI":"10.1016\/S1473-3099(23)00118-4"},{"key":"9679_CR25","doi-asserted-by":"crossref","unstructured":"Lai CC, Wang YH, Chen KH, Chen CH, Wang CY. The clinical efficacy and safety of anti-viral agents for non-hospitalized patients with COVID-19: a systematic review and network Meta-analysis of Randomized controlled trials. Viruses. 2022;14(8).","DOI":"10.3390\/v14081706"},{"issue":"6","key":"9679_CR26","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S1473-3099(23)00056-7","volume":"23","author":"CKH Wong","year":"2023","unstructured":"Wong CKH, Lau KTK, Leung GM. Real-world effectiveness of nirmatrelvir\/ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants. Lancet Infect Dis. 2023;23(6):639\u201340.","journal-title":"Lancet Infect Dis"},{"key":"9679_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ijid.2023.08.003","volume":"135","author":"EV Low","year":"2023","unstructured":"Low EV, Pathmanathan MD, Chidambaram SK, Kim WR, Lee WJ, Teh ZW, et al. Real-world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk patients with COVID-19 during Omicron BA.4, BA.5 and XBB subvariants dominance in Malaysia: a retrospective cohort study. Int J Infect Dis. 2023;135:77\u201383.","journal-title":"Int J Infect Dis"},{"issue":"6","key":"9679_CR28","doi-asserted-by":"publisher","first-page":"807","DOI":"10.7326\/M22-3565","volume":"176","author":"KL Bajema","year":"2023","unstructured":"Bajema KL, Berry K, Streja E, Rajeevan N, Li Y, Mutalik P, et al. Effectiveness of COVID-19 Treatment with Nirmatrelvir-Ritonavir or Molnupiravir among U.S. veterans: Target Trial Emulation Studies with one-Month and Six-Month outcomes. Ann Intern Med. 2023;176(6):807\u201316.","journal-title":"Ann Intern Med"},{"issue":"9596","key":"9679_CR29","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of Observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453\u20137.","journal-title":"Lancet"},{"key":"9679_CR30","unstructured":"Ministry of Health Malaysia. Clinical Management of Confirmed COVID-19 Case in Adult and Paediatric 2022. https:\/\/covid-19.moh.gov.my\/garis-panduan\/garis-panduan-kkm\/ANNEX-2E-CLINICAL-MANAGEMENT-OF-CONFIRMED-COVID-19-31052022.pdf. Accessed 15 Nov 2023."},{"issue":"1","key":"9679_CR31","doi-asserted-by":"publisher","first-page":"e0296488","DOI":"10.1371\/journal.pone.0296488","volume":"19","author":"PSK Tok","year":"2024","unstructured":"Tok PSK, Kang KY, Ng SW, Ab Rahman N, Syahmi MA, Pathmanathan MD, et al. Post COVID-19 condition among adults in Malaysia following the Omicron wave: a prospective cohort study. PLoS ONE. 2024;19(1):e0296488.","journal-title":"PLoS ONE"},{"key":"9679_CR32","unstructured":"World Health Organization. Post COVID-19 condition (COVID-19) 2022 https:\/\/www.who.int\/europe\/news-room\/fact-sheets\/item\/post-covid-19-condition. Accessed 15 November 2023."},{"issue":"1","key":"9679_CR33","doi-asserted-by":"publisher","first-page":"7363","DOI":"10.1038\/s41467-022-35240-2","volume":"13","author":"K Magnusson","year":"2022","unstructured":"Magnusson K, Kristoffersen DT, Dell\u2019Isola A, Kiadaliri A, Turkiewicz A, Runhaar J, et al. Post-covid medical complaints following infection with SARS-CoV-2 omicron vs Delta variants. Nat Commun. 2022;13(1):7363.","journal-title":"Nat Commun"},{"issue":"1","key":"9679_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/infdis\/jiad382","volume":"229","author":"P Hedberg","year":"2024","unstructured":"Hedberg P, Naucl\u00e9r P. Post-COVID-19 Condition after SARS-CoV-2 infections during the Omicron Surge vs the Delta, Alpha, and wild type periods in Stockholm, Sweden. J Infect Dis. 2024;229(1):133\u20136.","journal-title":"J Infect Dis"},{"issue":"2","key":"9679_CR35","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1016\/S2213-2600(22)00501-X","volume":"11","author":"C Saunders","year":"2023","unstructured":"Saunders C, Sperling S, Bendstrup E. A new paradigm is needed to explain long COVID. Lancet Respiratory Med. 2023;11(2):e12\u20133.","journal-title":"Lancet Respiratory Med"},{"issue":"7","key":"9679_CR36","doi-asserted-by":"publisher","first-page":"e28951","DOI":"10.1002\/jmv.28951","volume":"95","author":"TH Liu","year":"2023","unstructured":"Liu TH, Wu JY, Huang PY, Tsai YW, Lai CC. The effect of nirmatrelvir-ritonavir on the long-term risk of neuropsychiatric sequelae following COVID-19. J Med Virol. 2023;95(7):e28951.","journal-title":"J Med Virol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09679-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-09679-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09679-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T06:03:53Z","timestamp":1722837833000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-09679-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9679"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-09679-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,5]]},"assertion":[{"value":"31 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was registered in the National Medical Research Register and approved by the Medical Research and Ethics Committee, Ministry of Health Malaysia (NMRR ID-22-00938-2YN).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The databases consist of individual-level information. The deidentified data that support the findings of this study are available upon reasonable request, and with protocol approved by the Medical Research and Ethics Committee, Ministry of Health Malaysia.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing statement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that they have no conflict of interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"780"}}